EVO:NASDAQ
Evotec SE
US$3.14
arrow_downward
-0.32%(-0.0100) 1D
US$3.05
arrow_downward
-2.87% (-0.090)today개장 전 거래
휴장: 4월 27일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoEVO의 주요 통계 생성 중...
시가
US$3.08
고가
US$3.16
저가
US$3.08
시가총액
11.08억
평균 거래량
11.94만
거래량
1.08천
52주 최고가
US$4.80
52주 최저가
US$2.31
EPS
-US$0.34
베타
1.90
유통 주식수
3.56억
직원 수
4천
뉴스 기사
웹 소스 기반
Investing.com 한국어
·
10분 전
스카이코프 솔라, 나스닥 최저 입찰가 규정 준수 회복
Investing.com 한국어
·
40분 전
InflaRx, Nasdaq 최저 호가 요건 재준수
EBC Financial Group
·
51분 전
나스닥 랠리: 2026년 성장주가 미래를 어떻게 선반영하는가
프로필
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE에 관한 정보